期刊文献+

应用低剂量激素治疗预防围绝经期妇女骨质疏松症的观察研究 被引量:7

Preventive effects of small dose estrogen and progesterone on prevention and treatment of perimenopausal osteoporosis
下载PDF
导出
摘要 目的研究低剂量雌孕激素治疗预防绝经后骨质疏松症的疗效。方法将140例围绝经期和绝经后妇女随机分为4组,给药方案分别是:A组(35例):每日戊酸雌二醇(E2V)1mg+醋酸甲羟孕酮(MPA)2mg;B组(35例):每日结合雌激素(CEE)0.45mg+MPA2mg;C组(35例):每日替勃龙1.25mg;D组(35例):每日服用中成药坤泰胶囊,3次日,4粒次。共服药1年,每组均同时给予碳酸钙400mg并推荐服用维生素D200IU。于用药前后应用DEXA法测腰椎与髋骨的骨密度,同时B超监测子宫内膜厚度,患者每日记录阴道出血和乳房症状。结果三种HT方案均能有效维持BMD,效果优于中药,且未引起子宫内膜和乳腺增生,患者依从性与中药组相比无显著性差异。结论低剂量不间断HT可以安全有效地预防围绝经期及绝经后妇女的骨量丢失。 Objective To study the effect of small dose hormone therapy on prevention of postmenopausal osteoporosis. Methods One hundred and forty peri- and post- menopausal women were randomly divided into 4 groups : group A(35 cases) received estradiol valerate ( E2 V) 1 mg + medroxypregesterone acetate(MPA) 2 mg per day;group B(35 cases) received conjugated estrogen(CE) 0. 45 mg+ MPA 2 mg per day; group C(35 cases) received livial 1.25 mg per day;group D(35 cases) received a kind of herbal drug-geng-nian-ning-xin. All subjects were given calcium carbonate 400 mg per day with the previeus prescription for one year and 200 IU vitamin D was recommended everyday. Before the drug administration and 12 months after the study, the bone mineral density(BMD) of lumbar verteba and hip bone was measured by dual-energy X-ray absorptiometry and the endometrium by B-ultrasound. Vaginal bleeding and breast tenderness were recorded by the subjects themselves. Results All subjects in group A, B and C maintained relatively higher BMD than those in group D hyperplasia of endometrium or breast. All women have similar compliance regardless of the group assignment. Conclusions Persistent small dose of estrogen and progesterin can prevent postmenopausal osteoporosis effectively and safely.
出处 《中国骨质疏松杂志》 CAS CSCD 2005年第4期423-426,共4页 Chinese Journal of Osteoporosis
基金 国家十五攻关资助项目(2001BA702B03)
关键词 骨质疏松 性激素 治疗 低剂量 预防 围绝经期 妇女 Osteoporosis Hormone therapy Small dose
  • 相关文献

参考文献7

  • 1Gallagher JC,Baylink DJ,Freeman R,et al.Prevention of bone loss with tibolone in postmenopausal woman:results of two randomized,double-blind,placebo-controlled,dose-finding studies.J Clin Endocrinol Metab,2001,86:4717-4726.
  • 2Lindsay R,Gallagher JC,Kleerekoper M,et al.Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in postmenopausal women.JAMA,2002,287:2668-2676.
  • 3Mizunuma H,Okano H,Soda M,et al.Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy:a 2-year prospective study.Maturitas,1997,27:69-76.
  • 4Women's Health Initiative Investigators.Risks and benefits of estrogen plus progestin in postmenopausal women.Principal results from the Women's Health Initiative randomized controlled edtrial.JAMA,2002,288:321-333.
  • 5Gambrell RD Jr.Improving continuation rates for hormone replacement therapy.Menopause,2002,9:3-5.
  • 6Michael Wells,David W Sturdee,David H Barlow,et al.Effect on endometrium of long term treatment with continuous combined estogen-progestogen replacement therapy:follow up study.BM J,2002,325:239.
  • 7Nurse P.Collabborative group on hormonal factors in breast cancer.breast cancer and HRT:collaborative reanalysis of data from 51epidemiological studies fo 52705 women with breast cancer.Lancet,1997,350:1047-1059.

同被引文献71

引证文献7

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部